Assessment of Bone Metastases, Skeletal-Related Events and Bone-Targeting Agents in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Systemic Therapy (Meet-URO 33 Study Subanalysis)
In brief
Bone metastases slash median survival to 27 months versus 102 months without them
In a multicenter study of 1,696 metastatic renal cell carcinoma patients, 31% had bone metastases, which were linked to a median overall survival of 27 months compared with 102 months for those without bone spread. Bone involvement also shortened progression-free survival and was associated with higher skeletal-related events, underscoring a persistent unmet need.
- Journal
- Clinical genitourinary cancer (Q1)
- Published
- 25 August 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Anna Amela Valsecchi, Sara Elena Rebuzzi, Maria Concetta Cursano, Francesco Pantano, Rossana Berardi, Davide Bimbatti, et al.
- PMID
- 42760246
- DOI
- 10.1016/j.clgc.2026.102654
Why clinicians should know about it
- Picked for Urology (paper of the day, 21 September 2026): Metastatic RCC outcomes, bone metastases prognostic factor
Abstract
INTRODUCTION: Bone metastases (BMs) in patients with metastatic renal cell carcinoma (mRCC) negatively affect survival, quality of life, and increase the risk of skeletal-related events (SREs). Evidence remains limited in the era of first-line immune-based combinations. PATIENTS AND METHODS: Meet-URO 33 is an Italian multicenter observational retrospective-prospective study enrolling mRCC patients receiving first-line therapy. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), clinical characterization, incidence of SREs, and impact of bone-targeting agents (BTAs). Survival was analyzed using the Kaplan-Meier method, log-rank test and Cox proportional hazards model. RESULTS: A total of 1696 patients enrolled between 2021 and 2025 were included; 526 (31%) had BMs at metastatic diagnosis. Patients with BMs more frequently had poorer performance status and unfavorable International mRCC Database Consortium (IMDC) risk. The presence of BMs was associated with significantly worse OS (median 26.9 vs. 102.1 months; hazard ratio [HR] 0.53; P < .001) and worse PFS (median 14.2 vs. 19.4 months; HR 0.71; P < .001), with OS and PFS varying according to first-line regimen. Worse OS persisted across IMDC risk classes and treatment types; PFS differences were not significant in favorable/intermediate IMDC risk groups and with tyrosine kinase inhibitor monotherapy. Neither anatomical site nor number of BMs significantly affected OS. SRE incidence in patients with BMs was 26.8%, more frequent with spinal, rib, or other-site involvement, and more common in BTA-treated patients (22.2% vs. 13.7%, P = .03), likely reflecting selection bias. CONCLUSION: BMs are confirmed a negative prognostic factor in mRCC involving persistent unmet clinical needs.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.